193 related articles for article (PubMed ID: 17133323)
1. [The prevalence and pharmacological cost of Parkinson's disease in Spain].
Abasolo-Osinaga E; Abecia-Inchaurregui LC; Fernández-Díaz E; Barcenilla-Laguna A; Bañares-Onraita T
Rev Neurol; 2006 Dec 1-15; 43(11):641-5. PubMed ID: 17133323
[TBL] [Abstract][Full Text] [Related]
2. [Estimation of the prevalence of Parkinson's disease in Asturia, Spain. A pharmacoepidemiological study of the consumption of antiparkinson drugs].
Martínez-Suárez MM; Blázquez-Menes B
Rev Neurol; 2000 Dec 1-15; 31(11):1001-6. PubMed ID: 11190861
[TBL] [Abstract][Full Text] [Related]
3. [Use of antiparkinsonian agents in Castilla-La Mancha. Estimate of prevalence of Parkinson disease].
Criado-Alvarez JJ; Romo-Barrientos C; Martínez-Hernández J; González-Solana I
Rev Neurol; 1998 Sep; 27(157):405-8. PubMed ID: 9774809
[TBL] [Abstract][Full Text] [Related]
4. [The estimation of prevalence of Parkinson disease in Navarra. An epidemiological study of the consumption of anti-parkinsonian drugs].
Artázcoz Sanz MT; Viñes Rueda JJ
Rev Esp Salud Publica; 1995; 69(6):479-85. PubMed ID: 8789360
[TBL] [Abstract][Full Text] [Related]
5. [The evolution of use of anti-Parkinson drugs in Spain].
Montané E; Vallano Ferraz A; Castel JM
Rev Neurol; 2002 Apr 1-15; 34(7):612-7. PubMed ID: 12080509
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.
Hudry J; Rinne JO; Keränen T; Eckert L; Cochran JM
Ann Pharmacother; 2006 Apr; 40(4):651-7. PubMed ID: 16569799
[TBL] [Abstract][Full Text] [Related]
7. A pharmacoepidemiological study of the consumption of antiparkinson drugs in the Basque Autonomous Community (Spain) (1992-2004).
Osinaga EA; Inchaurregui LC; Ikobaltzeta IE; Alonso NB; Del Pozo JG
Parkinsonism Relat Disord; 2007 Dec; 13(8):500-4. PubMed ID: 17532251
[TBL] [Abstract][Full Text] [Related]
8. Costs of Parkinson's disease and antiparkinsonian pharmacotherapy: an Italian cohort study.
Winter Y; von Campenhausen S; Reese JP; Balzer-Geldsetzer M; Longo K; Spiga G; Boetzel K; Eggert K; Oertel WH; Dodel R; Barone P
Neurodegener Dis; 2010; 7(6):365-72. PubMed ID: 20523028
[TBL] [Abstract][Full Text] [Related]
9. Drug costs for patients with Parkinson's disease in two different European countries.
Vossius C; Gjerstad M; Baas H; Larsen JP
Acta Neurol Scand; 2006 Apr; 113(4):228-32. PubMed ID: 16542161
[TBL] [Abstract][Full Text] [Related]
10. Treatment of Parkinson's disease in Spain.
Grandas F; Kulisevsky J
Mov Disord; 2003 Jan; 18(1):87-9. PubMed ID: 12518304
[TBL] [Abstract][Full Text] [Related]
11. [Dispensation and cost of antimicrobials in Spain (1998-2000)].
Abasolo Osinaga E; Abecia Inchaurregui LC; Bañares Onraita MT; Rada Fernández de Jáuregui D
Rev Esp Quimioter; 2005 Dec; 18(4):300-7. PubMed ID: 16446789
[TBL] [Abstract][Full Text] [Related]
12. Estimation of incidence and prevalence of Parkinson's disease in the elderly using pharmacy records.
van de Vijver DA; Roos RA; Jansen PA; Porsius AJ; de Boer A
Pharmacoepidemiol Drug Saf; 2001; 10(6):549-54. PubMed ID: 11828838
[TBL] [Abstract][Full Text] [Related]
13. [Daily defined doses of parkinsonian drugs in Alcoi].
Manzanares R; Matías-Guiu J; Provencio R; Falip R; López-Arlandis J; Martín R; Ruiz C
Rev Neurol; 1996 Apr; 24(128):440-2. PubMed ID: 8721923
[TBL] [Abstract][Full Text] [Related]
14. [Epidemiology of parkinsonism in the Guadalajara Health Area].
Martínez-Pérez JA; Ortiz-García R; González-Zerega A; López-Gosling I; Guzmán A; Dragomir E
Semergen; 2014 Sep; 40(6):305-12. PubMed ID: 24556169
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of Parkinson's disease in a developing country: a retrospective cost analysis in Shanghai, China.
Wang G; Cheng Q; Zheng R; Tan YY; Sun XK; Zhou HY; Ye XL; Wang Y; Wang Z; Sun BM; Chen SD
Mov Disord; 2006 Sep; 21(9):1439-43. PubMed ID: 16773620
[TBL] [Abstract][Full Text] [Related]
16. Prescribing pattern in Parkinson's disease: are cost and efficacy overriding factors?
Tan EK; Yeo AP; Tan V; Pavanni R; Wong MC
Int J Clin Pract; 2005 May; 59(5):511-4. PubMed ID: 15857344
[TBL] [Abstract][Full Text] [Related]
17. Use of antiparkinsonian drugs in Denmark: results from a nationwide pharmacoepidemiological study.
Brandt-Christensen M; Kvist K; Nilsson FM; Andersen PK; Kessing LV
Mov Disord; 2006 Aug; 21(8):1221-5. PubMed ID: 16671076
[TBL] [Abstract][Full Text] [Related]
18. Treatment benefit correlates with increase of daily drug costs in Parkinson's disease clinics.
Müller T; Voss B; Hellwig K; Przuntek H
NeuroRehabilitation; 2003; 18(3):271-5. PubMed ID: 14530592
[TBL] [Abstract][Full Text] [Related]
19. Punding prevalence in Parkinson's disease.
Miyasaki JM; Al Hassan K; Lang AE; Voon V
Mov Disord; 2007 Jun; 22(8):1179-81. PubMed ID: 17230464
[TBL] [Abstract][Full Text] [Related]
20. Prescribing patterns of antiparkinsonian agents in Europe.
Rosa MM; Ferreira JJ; Coelho M; Freire R; Sampaio C
Mov Disord; 2010 Jun; 25(8):1053-60. PubMed ID: 20222132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
